February 16, 2022 -- ImmunityBio has successfully acquired a leasehold interest in an International Organization for Standardization Class 5 pharmaceutical manufacturing space in western New York from global pharmaceutical company Athenex. The full-scale facility enables ImmunityBio to substantially expand and diversify its existing manufacturing capacity in the U.S. and through its strategic collaborators in Africa.
The state-of-the-art biotech production facility, located in Dunkirk, NY, includes clean rooms for upstream and downstream manufacturing activities, as well as fill and finish and large-scale lyophilization capabilities.
ImmunityBio is a clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases.
Copyright © 2022 scienceboard.net